PATH Stock Slips Onto Watchlists After UBS Target Cut

UiPath Inc. stocks have been trading up by 5.03 percent following upbeat coverage of its expanding AI automation capabilities.

Live Update At 15:01:57 EDT: On Tuesday, July 28, 2026 UiPath Inc. stock [NYSE: PATH] is trending up by 5.03%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Quick Financial Overview

UiPath Inc. sits in that tricky middle ground where the story is improving, but the market is not ready to reward it aggressively. PATH is trading near $10–$12, below the mean Street target of about $13.47, so on paper there is upside. But the recent UBS move, cutting its PATH target from $13 to $12 while staying Neutral, tells traders that big money is not chasing this name yet.

On the chart, PATH has climbed from a low around $10.20 on 2026/07/23 to roughly $12.21 by 2026/07/28, a solid rebound of nearly 20% in a few sessions. The intraday 5‑minute tape shows tight action around $12 with steady higher lows, which usually reflects controlled, algorithmic buying rather than wild speculation.

Fundamentally, UiPath posted about $1.61B in annual revenue with a fat 83% gross margin and positive net income last quarter. PATH is throwing off free cash flow of roughly $129.2M, trades at about 3.2 times sales, carries very low debt, and has over $1.3B in cash and short‑term investments. For short-term traders, this mix of decent growth, cash strength, and subdued sentiment creates a classic “show me” stock.

Why Traders Are Watching PATH After The UBS Cut

The UBS target cut is the headline, but the context around PATH matters just as much. When a major bank trims UiPath’s price target from $13 to $12 and still calls it Neutral, it signals lukewarm confidence. Not a disaster. Not a love affair either. For active traders, that usually means the stock trades in ranges until a new catalyst breaks the stalemate.

Look at the recent action. PATH got slammed down near $10.20, then ripped back above $12 within a few trading days. That’s textbook volatility, the kind momentum traders seek. Yet, with the Street’s average target only around $13.47, most analysts are essentially saying, “We don’t see a massive run from here unless something big changes.” The overall Hold stance around UiPath reinforces that view.

Under the hood, the business is not broken. UiPath generated $418.4M in quarterly revenue with an 83% gross margin and positive operating income. Free cash flow is strong, leverage is minimal, and PATH’s current ratio above 2 shows a comfortable liquidity cushion. That financial foundation is why PATH is not being priced like a distressed software name.

For traders, this combination — solid fundamentals, cautious Wall Street, and a volatile chart — turns UiPath into a tactical trading vehicle rather than a conviction long-term hold. Breakouts above recent highs near $12.50–$12.55 could spark short-covering pops toward the low‑$13s, while failed pushes may reload the $11–$11.50 zone as a trading range. PATH belongs on watch for clean technical setups, not blind dip-buying.

Conclusion

UiPath sits at an interesting crossroads. PATH is profitable on a GAAP basis, delivers strong free cash flow, and keeps debt low, which is rare for a still-growing automation platform. Yet UBS just trimmed its target from $13 to $12 and stayed Neutral, while the broader Street keeps PATH at Hold with a mean target near $13.47. That is the definition of “prove it” sentiment.

For short-term traders, that stance is not a problem — it is the opportunity. When the crowd is lukewarm on UiPath, strong earnings beats, big customer wins, or new AI‑driven products can trigger sharp repricings. Until then, PATH is likely to remain a chart-driven story. The recent rebound from about $10 to above $12 shows there is plenty of speculative capital sitting on the sidelines waiting for signals. In an environment like this, chasing every spike can be dangerous; as millionaire penny stock trader and teacher Tim Sykes, says, “There is always another play around the corner; don’t chase just because you feel FOMO.” Keeping that trading mentality helps when deciding whether to wait for better entries or sit in cash until a higher‑probability setup emerges.

The key, as always in this market, is risk control. UiPath has the liquidity and margins to survive rough patches, but no analyst target or consensus rating guarantees a smooth ride. As Tim Sykes loves to remind traders, “Discipline and risk management matter more than any hot stock tip.” Apply that mindset to PATH — focus on the levels, respect your stops, and let the chart, not the hype, guide your trades.

This is stock news, not investment advice. Timothy Sykes News delivers real-time stock market news focused on key catalysts driving short-term price movements. Our content is tailored for active traders and investors seeking to capitalize on rapid price fluctuations, particularly in volatile sectors like penny stocks. Readers come to us for detailed coverage on earnings reports, mergers, FDA approvals, new contracts, and unusual trading volumes that can trigger significant short-term price action. Some users utilize our news to explain sudden stock movements, while others rely on it for diligent research into potential investment opportunities.

Dive deeper into the world of trading with Timothy Sykes, renowned for his expertise in penny stocks. Explore his top picks and discover the strategies that have propelled him to success with these articles:

• Penny Stocks Trading Guide
• Best Penny Stocks Under $1 to Buy Today
• Top 8 Penny Stocks to Watch on Robinhood

Once you’ve got some stocks on watch, elevate your trading game with StocksToTrade the ultimate platform for traders. With specialized tools for swing and day trading, StocksToTrade will guide you through the market’s twists and turns.
Dig into StocksToTrade’s watchlists here:

• AI Penny Stocks
• Robinhood Penny Stocks
• Top Biotech Stocks